Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04053868 · ClinicalTrials.gov registry record · NA
Evaluating the Comparative Pharmacokinetics of Nicotine After Administration Via JUUL or Tobacco Cigarettes
A NA study of Tobacco Smoking and Vaping, sponsored by University of California, San Francisco.
- Completed
- Registry status
- NA
- Development phase
- 17
- Enrollment target
- 2
- Study locations
NCT04053868: Completed NA study of Tobacco Smoking and Vaping, sponsored by University of California, San Francisco.
NCT04053868 is a NA study of Tobacco Smoking and Vaping that has completed, run by University of California, San Francisco. The registered enrollment target is 17 participants, below the 477-participant average among 38 other Tobacco Smoking trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04053868, a NA study of Tobacco Smoking and Vaping, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- NA
- Development phase
- 17 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is an observational, crossover design that will examine the pharmacokinetics and pharmacodynamics of impact of smoking tobacco cigarettes or vaping the JUUL electronic cigarette.
Primary Outcome
Plasma nicotine area under the concentrated time curve (AUC) (ng/ml\*h)
Conditions Studied
Interventions
- OTHER JUUL
- OTHER Tobacco
Study Locations (2)
California
- Zuckerberg San Francisco General Hospital - San Francisco
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2019-12-09 |
| Est. Completion | 2022-03-31 |
| Phase | NA |
What the finished NCT04053868 record still lists
NCT04053868 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 477-participant average among 38 other Tobacco Smoking trials with a reported enrollment target (96% lower).
The record links to 5 conditions, with Tobacco Smoking appearing as the primary indexed condition, and to 2 interventions - of which JUUL is the first listed.
NCT04053868 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04053868 about?
NCT04053868 is a clinical study titled "Evaluating the Comparative Pharmacokinetics of Nicotine After Administration Via JUUL or Tobacco Cigarettes". This is an observational, crossover design that will examine the pharmacokinetics and pharmacodynamics of impact of smoking tobacco cigarettes or vaping the JUUL electronic cigarette.
What is the current status of trial NCT04053868?
This trial is currently completed. It is a NA study. The enrollment target is 17 participants. The study started on 2019-12-09. Estimated completion is 2022-03-31.
What conditions does trial NCT04053868 study?
This clinical trial studies the following conditions: Tobacco Smoking, Vaping, Nicotine Administration & Dosage, E-cigarettes, E-Liquid.
What interventions are being tested in trial NCT04053868?
The interventions under investigation include: JUUL (OTHER), Tobacco (OTHER).
Who is sponsoring clinical trial NCT04053868?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04053868 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tobacco Smoking
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04053868's enrollment target sits among peer trials
17 35th of 38 higher than 4 of 38 other Tobacco Smoking trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tobacco Smoking trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reach Through Equitable Implementation in Utah
RECRUITING · NA
-
Development of a Smoking Cessation Video Series
RECRUITING · NA
-
Trauma-Informed Care for Smoking Cessation for Pregnancy
RECRUITING · NA
-
A Study Evaluating the Use of an Indoor Air Quality Monitor to Promote a Smoke-free Home
RECRUITING · NA
-
Using Novel Behavioral Economic Measures to Characterize Dual Marijuana and Tobacco Use in Young Adults
RECRUITING · NA
-
CONNECT Cancer Survivors With Tobacco Treatment
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI